British Journal of Ophthalmology · 2006 · 44 citations · 53 references
MedicineOphthalmologySurgeryOcular Drug DeliveryOcular PharmacologyOphthalmic SurgeryOcular PharmacokineticsRetinal PharmacotherapyUveal SurgeryVitreoretinal SurgeryVitreous Drug DeliveryVitreous SurgeryDrug Clearance From The Vitreous BodyDrug Delivery To The VitreousEndophthalmitis SurgeryIntravitreal Drug KineticsResidence TimeResidence Time EstimationVitreous Drug DistributionVitreous Retention Time
AIM: To determine the duration of residence of triamcinolone in the vitrectomised eye. METHODS: 23 eyes of 23 patients underwent intravitreal injection of high dose (20 mg) decanted triamcinolone acetonide (Kenalog) at the conclusion of vitrectomy surgery or in previously vitrectomised eyes with macular oedema from diabetes, uveitis, cataract surgery, or other surgery. RESULTS: The median time to disappearance of triamcinolone in the vitrectomised eye was 113 days (95% confidence interval (CI) 85 to 191). In the phakic eyes the median time to disappearance was 191 days (95% CI 148 to 191). In the pseudophakic eyes the median time to disappearance was 102 days (95% CI 85 to 113). This difference was not significant (p = 0.12). There were no cases of endophthalmitis or severe inflammatory reaction. Five eyes (22%) experienced intraocular pressure rise >/=10 mm Hg. CONCLUSIONS: High dose decanted intravitreal triamcinolone has a median residence time of 113 days in the vitrectomised eye. Although this appears to be shorter than in the non-vitrectomised eye, this study suggests that a sufficient duration of action will be present to be clinically useful.
53
The Lens Opacities Classification System III
L.T. Chylack · Archives of Ophthalmology · 1993 · 2.9K citations
Intravitreal triamcinolone for refractory diabetic macular edema
Adam Martidis, Jay S. Duker, Paul B. Greenberg et al. · Ophthalmology · 2002 · 1K citations